TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39044224

Group type: EXPERIMENTAL
Intervention: Food Literacy and Nutrition (FLAN) curriculum
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nutrition information-only control
Number of subjects: 39
Study: 39044295

Group type: EXPERIMENTAL
Intervention: 12 hours of therapeutic cooling
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: 24 hours of therapeutic cooling
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: 48 hours of therapeutic cooling
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Shorter and longer duration arms (between 12 and 48 hours)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Normothermia (not explicitly mentioned as a control)
Number of subjects: 1800
Study: 39044381

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (10 mg/kg once) with fluconazole
Number of subjects: 168

Group type: COMPARATOR
Intervention: Fluconazole alone
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B with fluconazole
Number of subjects: 168
Study: 39044659

Group type: EXPERIMENTAL
Intervention: Staged PCI at earlier timing (5-7 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Staged PCI at later timing (12-14 weeks)
Number of subjects: 150
Study: 39044792

Group type: EXPERIMENTAL
Intervention: Real-time guiding using deep learning during echocardiography
Number of subjects: 0
Study: 39044797

Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 39044861

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: COVID-19 severe disease
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vaccine adverse effects after dose one
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: CD flares after SARS-CoV-2 infection
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Anti-spike titer after vaccination
Number of subjects: 300
Study: 39045032

Group type: EXPERIMENTAL
Intervention: EDucation on load management plus eXercise (EDX) delivered in 6 sessions over 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 64
Study: 39045079

Group type: EXPERIMENTAL
Intervention: Real-time guidance by deep learning (DL) for experienced sonographers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 39045200

Group type: EXPERIMENTAL
Intervention: Serial cardiac magnetic resonance (CMR) imaging
Number of subjects: 18

Group type: COMPARATOR
Intervention: C-reactive protein (CRP) assay
Number of subjects: 18
Study: 39045229

Group type: EXPERIMENTAL
Intervention: F3-App (interactive educational software)
Number of subjects: 0
Study: 39045391

Group type: EXPERIMENTAL
Intervention: Community mental health worker (CMHW) implementing Problem Management Plus (PM+)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tutors
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 39045392

Group type: EXPERIMENTAL
Intervention: Personalized, nature-based and other outdoor VR content for patient-caregiver dyads
Number of subjects: 0
Study: 39045484

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including training sessions for health workers, patient education materials, storytelling intervention, home BP self-monitoring, and expanded community health worker services.
Number of subjects: 671

Group type: COMPARATOR
Intervention: Comparison group received training sessions about hypertension prevention and management for health workers and patient education materials.
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 671
Study: 39045544

Group type: EXPERIMENTAL
Intervention: Toripalimab (240 mg) every 3 weeks plus nab-paclitaxel weekly for 12 weeks after four cycles of epirubicin-cyclophosphamide every 2 weeks
Number of subjects: 70
Study: 39045554

Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 1
Study: 39045754

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
Number of subjects: 100
Study: 39045758

Group type: EXPERIMENTAL
Intervention: High EVOO diet (4 tablespoons/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low EVOO diet (<1 teaspoon/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low EVOO diet followed by high EVOO diet
Number of subjects: 40
Study: 39045795

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for PTSD
Number of subjects: 0
Study: 39045819

Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P (SSTP) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study: 39046150

Group type: EXPERIMENTAL
Intervention: VISITECT CD4 Advanced Disease test
Number of subjects: 1604
Study: 39046157

Group type: EXPERIMENTAL
Intervention: Subcutaneous lenacapavir every 26 weeks
Number of subjects: 5338

Group type: EXPERIMENTAL
Intervention: Daily oral emtricitabine-tenofovir alafenamide (F/TAF)
Number of subjects: 5338

Group type: COMPARATOR
Intervention: Daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF; active control)
Number of subjects: 5338
Study: 39046314

Group type: EXPERIMENTAL
Intervention: Intra-articular hip injection with prior subcutaneous LA (2 mL of lidocaine 1%)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intra-articular hip injection without prior subcutaneous LA
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intra-articular hip injection with prior subcutaneous LA
Number of subjects: 41
Study: 39046333

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant inhibitors or inducers of cytochrome P450 3A4 and/or P-glycoprotein
Number of subjects: 0
Study: 39046616

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 618

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: FACT-GP5
Number of subjects: 618
Study: 39046635

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of natalizumab
Number of subjects: 153

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of natalizumab
Number of subjects: 153
Study: 39046647

Group type: EXPERIMENTAL
Intervention: Sanjie Analgesic Capsule (SAC) 1.6 g 3 times per day for 3 menstrual cycles
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo 1.6 g 3 times per day for 3 menstrual cycles
Number of subjects: 323
Study: 39046695

Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonist (LAMA)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: LAMA + long-acting β agonist
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Other inhaler treatments
Number of subjects: 414

Group type: COMPARATOR
Intervention: Inhaler treatment (general)
Number of subjects: 414
Study: 39046727

Group type: EXPERIMENTAL
Intervention: Dapagliflozin for 24 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 37
Study: 39046741

Group type: EXPERIMENTAL
Intervention: Early intervention group (pharmacist-led OAC prescription)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (delayed intervention, usual care)
Number of subjects: 80
Study: 39046767

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10 mg twice daily for ages ≥12 to <18 years; 5 mg twice daily for ages ≥6 to <12 years; 4 mg/m2 twice daily for ages ≥2 to <6 years)
Number of subjects: 45
Study: 39046783

Group type: EXPERIMENTAL
Intervention: PAC/SIR/TAC
Number of subjects: 28
Study: 39046800

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39046973

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05
Number of subjects: 82
Study: 39047125

Group type: EXPERIMENTAL
Intervention: Microserrated forceps
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional forceps
Number of subjects: 90
Study: 39047180

Group type: EXPERIMENTAL
Intervention: Heartfulness self-care program (4-week web-based program)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 203
Study: 39047219

Group type: EXPERIMENTAL
Intervention: Extended letrozole therapy (ELT)
Number of subjects: 1866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1866
Study: 39047238

Group type: EXPERIMENTAL
Intervention: Limited sampling strategies (LSSs) for mycophenolic acid (MPA)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Limited sampling strategies (LSSs) for mycophenolic acid (MPA) in high EHR group
Number of subjects: 84
Study: 39047240

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 488

Group type: COMPARATOR
Intervention: Chemotherapy-only
Number of subjects: 488
Study: 39047258

Group type: EXPERIMENTAL
Intervention: CPSP prevalence at 3 months
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CPSP prevalence at 24 months
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Pain intensity as a presurgical predictor for CPSP
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing as a presurgical predictor for CPSP
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Pain anxiety as a presurgical predictor for CPSP
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Group-based trajectory modeling for postsurgical pain
Number of subjects: 159
Study: 39047288

Group type: EXPERIMENTAL
Intervention: CT-assessed VAT index
Number of subjects: 3730

Group type: EXPERIMENTAL
Intervention: CT-assessed SAT
Number of subjects: 3730

Group type: EXPERIMENTAL
Intervention: VAT/SAT ratio
Number of subjects: 3730

Group type: EXPERIMENTAL
Intervention: Reference values for SAT and VAT
Number of subjects: 3730
Study: 39047811

Group type: EXPERIMENTAL
Intervention: PRISM intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 39047868

Group type: EXPERIMENTAL
Intervention: Creatine (20 g/day for 7 days)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3

Group type: COMPARATOR
Intervention: Creatine, Placebo, Control
Number of subjects: 3
Study: 39048019

Group type: EXPERIMENTAL
Intervention: Womed Leaf film inserted
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no Womed Leaf film)
Number of subjects: 160
Study: 39048132

Group type: EXPERIMENTAL
Intervention: Wearing a surgical face mask in public spaces for 14 days
Number of subjects: 4647

Group type: COMPARATOR
Intervention: Not wearing a surgical face mask in public places
Number of subjects: 4647
Study: 39048547

Group type: EXPERIMENTAL
Intervention: SCTV01E
Number of subjects: 9223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9223
Study: 39048549

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 39048608

Group type: EXPERIMENTAL
Intervention: Clesacostat (PF-05221304), an acetyl coA carboxylase inhibitor (ACCi), 25 mg dosage.
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 39048638

Group type: EXPERIMENTAL
Intervention: Standard-of-care plus durvalumab and oleclumab (experimental arm)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard-of-care (control arm)
Number of subjects: 52
Study: 39048701

Group type: EXPERIMENTAL
Intervention: Exercise + Manual Therapy (ETManual therapy)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Exercise alone (ET)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Exercise + Kinesio Tape (ETkinesiotape)
Number of subjects: 55
Study: 39048748

Group type: EXPERIMENTAL
Intervention: Novel polyp retrieval bag
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (polyp trap through instrument channel)
Number of subjects: 204
Study: 39048932

Group type: EXPERIMENTAL
Intervention: POINCARE-2 strategy (daily weighing and administration of treatments)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control period (standard care without POINCARE-2 strategy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: POINCARE-2 strategy
Number of subjects: 0
Study: 39048933

Group type: EXPERIMENTAL
Intervention: Physical exercise programme in primary care (aerobic and strengthening exercises, twice a week for 12 weeks, daily walks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Physical exercise programme in primary care
Number of subjects: 90

Group type: COMPARATOR
Intervention: Unsupervised home-based exercise (daily walks and sit-to-stand exercise)
Number of subjects: 90
Study: 39048985

Group type: EXPERIMENTAL
Intervention: Salivary paxillin levels in patients with OSCC
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Salivary paxillin levels in patients with OPMDs
Number of subjects: 45

Group type: COMPARATOR
Intervention: ROC analysis between OPMDs and OSCC
Number of subjects: 45
Study: 39049019

Group type: EXPERIMENTAL
Intervention: Sequential 4-channel neuromuscular electrical stimulation (NMES)
Number of subjects: 0
Study: 39049044

Group type: EXPERIMENTAL
Intervention: Diabetes-self management training (DSMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote glucose monitoring (RGM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored support from a community health worker (CHW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching study arms (for nonresponders)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessments of diabetes empowerment and diabetes-related distress
Number of subjects: 0
Study: 39049042

Group type: EXPERIMENTAL
Intervention: Biomarkers investigated (neuropsychological tests: MMSE and delayed free recall, brain glucose metabolism)
Number of subjects: 500
Study: 39049073

Group type: EXPERIMENTAL
Intervention: Orlistat (360 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 39049078

Group type: EXPERIMENTAL
Intervention: Diabetes shared medical appointments (SMAs)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Presence of additional resources for patients with diabetes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Presence of an effective key person (implementation champion)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low or managed employee turnover, strong baseline practice culture, previous experience delivering SMAs
Number of subjects: 22
Study: 39049087

Group type: EXPERIMENTAL
Intervention: Incretin effect measured as the difference between plasma insulin area under the curve during an oral glucose tolerance test (OGTT) and intravenous glucose infusion.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-diabetic controls (n=10)
Number of subjects: 30
Study: 39049092

Group type: EXPERIMENTAL
Intervention: Low intensity IMT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High intensity IMT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Mixed intensity IMT
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (no IMT)
Number of subjects: 92
Study: 39049121

Group type: EXPERIMENTAL
Intervention: Personalized intervention
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Standardized intervention
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual Care Control (UCC)
Number of subjects: 255
Study: 39049127

Group type: COMPARATOR
Intervention: Endovascular thrombectomy (EVT) within 6 hours (STAMINA-HERMES)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Endovascular thrombectomy (EVT) within 6-24 hours (STAMINA-AURORA)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) outside RCT-criteria
Number of subjects: 598
Study: 39049187

Group type: EXPERIMENTAL
Intervention: Water-filtered infrared A radiation (WIRA) whole-body hyperthermia combined with immune checkpoint inhibitor (ICI) therapy (tislelizumab)
Number of subjects: 18
Study: 39049618

Group type: EXPERIMENTAL
Intervention: Friction mechanics using elastomeric chain (160 g/side)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Frictionless mechanics using closing T-loops (0.017 × 0.025-inch TMA wire)
Number of subjects: 30
Study: 39049802

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metformin treatment with saline infusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metformin treatment with exendin(9-39)NH2 infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15
Study: 39049803

Group type: EXPERIMENTAL
Intervention: TAMP-delivered gemcitabine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Previous chemoradiation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Previous systemic chemotherapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: No prior treatment
Number of subjects: 43
Study: 39049828

Group type: EXPERIMENTAL
Intervention: Plasma from BCG vaccinated patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Plasma from placebo patients
Number of subjects: 39
Study: 39050403

Group type: EXPERIMENTAL
Intervention: Personalised blood pressure management
Number of subjects: 328

Group type: COMPARATOR
Intervention: Routine blood pressure management
Number of subjects: 328
Study: 39050483

Group type: EXPERIMENTAL
Intervention: BMI<25 kg/m²
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: BMI 25-40 kg/m²
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: BMI>40 kg/m²
Number of subjects: 118
Study: 39050586

Group type: EXPERIMENTAL
Intervention: Dora R1 (autonomous telemedicine call)
Number of subjects: 202
Study: 39050690

Group type: EXPERIMENTAL
Intervention: Comprehensive fall prevention model implemented in the community
Number of subjects: 11
Study: 39050802

Group type: EXPERIMENTAL
Intervention: 150mg SHR6390 on Day 1; 600mg efavirenz orally at night from Day 8-26; 150mg SHR6390 on Day 22
Number of subjects: 20

Group type: COMPARATOR
Intervention: 150mg SHR6390
Number of subjects: 20
Study: 39050912

Group type: EXPERIMENTAL
Intervention: 3D multiparametric ultrasound with computer-aided diagnosis (PCaVision)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 438
Study: 39051019

Group type: EXPERIMENTAL
Intervention: Omidenepag isopropyl (OMDI) 0.002%
Number of subjects: 370

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 370
Study: 39051098

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Invasive knee extension exercise testing
Number of subjects: 45
Study: 39051104

Group type: EXPERIMENTAL
Intervention: Vigorous exercise (≥6 metabolic equivalents for >60 hours per year)
Number of subjects: 1413

Group type: COMPARATOR
Intervention: Nonvigorous exercise
Number of subjects: 1413
Study: 39051647

Group type: EXPERIMENTAL
Intervention: Linear-array endoscopic ultrasound (EUS)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Combined use of EUS and NBI
Number of subjects: 79
Study: 39051653

Group type: EXPERIMENTAL
Intervention: Adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control cohort (no adjuvant HAIC)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Training cohort (imaging-based model)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control group (high-risk adjuvant HAIC)
Number of subjects: 470
Study: 39052054

Group type: EXPERIMENTAL
Intervention: Dual-layer cone-beam CT 75 keV monoenergetic images
Number of subjects: 27
Study: 39052070

Group type: EXPERIMENTAL
Intervention: Death Cafés for burnout prevention
Number of subjects: 0
Study: 39052138

Group type: EXPERIMENTAL
Intervention: Growth chart extrapolation
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Parents' report
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Height measurement alongside the body with a tape measure
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Board length use
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Body segment extrapolations
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Body segment measurement
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Body segment-based techniques
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Simple techniques like growth chart extrapolation
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Length board measurement
Number of subjects: 476
Study: 39052163

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 187
Study: 39052241

Group type: EXPERIMENTAL
Intervention: Self-adjustment group using Lexie B2 hearing aids
Number of subjects: 28

Group type: COMPARATOR
Intervention: In situ audiometry group using Lexie B2 Plus hearing aids
Number of subjects: 28
Study: 39052242

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa, 1200 mg, intravenously once every 2 weeks
Number of subjects: 146
Study: 39052256

Group type: EXPERIMENTAL
Intervention: Atezolizumab, 1200 mg intravenously, administered on day 1 of each 21-day cycle for four cycles, followed by chemoradiation therapy (CRT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Atezolizumab, 1200 mg every 21 days continued for 1 year after CRT
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Atezolizumab, 1200 mg, as part of the treatment regimen
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Atezolizumab treatment
Number of subjects: 62
Study: 39052289

Group type: EXPERIMENTAL
Intervention: Health system-embedded deprescribing intervention
Number of subjects: 2367

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 2367
Study: 39052328

Group type: EXPERIMENTAL
Intervention: Mobile Link intervention
Number of subjects: 0
Study: 39052330

Group type: EXPERIMENTAL
Intervention: eMOTIVA app
Number of subjects: 300
Study: 39052335

Group type: EXPERIMENTAL
Intervention: Web-based resilience-enhancing program (4 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study: 39052473

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39052647

Group type: EXPERIMENTAL
Intervention: Culturally appropriate text message boosters in Swahili coupled with a brief negotiational intervention (BNI) for alcohol use reduction.
Number of subjects: 0